External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Haematology Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Dec 9 / Roche and Genentech
Clonal Hematopoiesis in Patients with Chronic Lymphocytic Leukemia Treated with Fixed-Duration Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Insights from the Randomized CLL14 Trial
CLL14 is a Phase III trial of venetoclax-obinutuzumab versus chlorambucil-obinutuzumab in patients with previously untreated chronic lymphocytic leukemia. Data on clonal hematopoiesis in patients from the CLL14 trial are presented.
Haematology Oncology Chronic Lymphocytic Leukaemia ASH-2024

Sign up or login to unlock the full suite of MEDICALLY features
Dec 8 / Roche and Genentech
Venetoclax May Overcome the Prognostic Disadvantage of Short Telomeres Regarding Progression Free Survival in Previously Untreated CLL Patients with Coexisting Conditions: A Study By the German CLL Study Group (GCLLSG)
CLL14 is a Phase III trial of venetoclax-obinutuzumab versus chlorambucil-obinutuzumab in patients with previously untreated chronic lymphocytic leukemia. Data are presented on telomere length and its association with survival clinical outcomes, in patients with coexisting conditions from the CLL14 trial.
Haematology Oncology Chronic Lymphocytic Leukaemia ASH-2024

Sign up or login to unlock the full suite of MEDICALLY features
Dec 8 / Roche and Genentech
CRISTALLO: Results from a Phase III Trial of Venetoclax-Obinutuzumab versus Fludarabine, Cyclophosphamide and Rituximab or Bendamustine-Rituximab in Patients with Untreated Chronic Lymphocytic Leukemia Without Del(17p) or TP53 Mutations
CRISTALLO is a Phase III trial comparing venetoclax-obinutuzumab versus fludarabine, cyclophosphamide, and rituximab or bendamustine-rituximab in patients with untreated chronic lymphocytic leukemia without del(17p) or TP53 mutations. Efficacy and safety results are presented.
Haematology Oncology Chronic Lymphocytic Leukaemia ASH-2024

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.